Bioage Labs Inc (BIOA)

Panoramica Notizia Cronologia dei prezzi Forum Previsione

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Bioage Labs Inc Stock (BIOA) Company Profile

Bioage Labs Inc

Healthcare (1170)

510-806-1445

1445A SOUTH 50TH STREET, RICHMOND

Prossima data di guadagno

Ultimi documenti SEC

BIOA's Discussions on Twitter

Confronta BIOA con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
BIOA Bioage Labs Inc	4.28	157.02M	0	0	0	0.00
RGC Regencell Bioscience Holdings Ltd	21.73	303.95B	0	-5.87M	-767.30K	-0.45
ZTS Zoetis Inc	157.23	74.39B	9.29B	2.52B	2.28B	5.57
HLN Haleon Plc Adr	10.50	48.97B	14.35B	1.85B	0	0.4023
TAK Takeda Pharmaceutical Co Adr	14.97	47.39B	30.08B	710.16M	4.45B	0.2182
TEVA Teva Pharmaceutical Industries Ltd Adr	17.00	20.17B	16.54B	-1.64B	749.00M	-1.45

Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-02-28	Iniziato	William Blair	Mkt Perform
2024-12-10	Downgrade	Morgan Stanley	Overweight → Underweight
2024-12-09	Downgrade	Citigroup	Buy → Neutral
2024-12-09	Downgrade	Jefferies	Buy → Hold
2024-10-21	Iniziato	Citigroup	Buy
2024-10-21	Iniziato	Jefferies	Buy
2024-10-21	Iniziato	Morgan Stanley	Overweight

Mostra tutto

Bioage Labs Inc Borsa (BIOA) Ultime notizie

Bioage Labs Inc Azioni (BIOA) Dati Finanziari

Non sono disponibili dati finanziari per Bioage Labs Inc (BIOA). Controlla altri titoli per ulteriori informazioni.

Bioage Labs Inc Azioni (BIOA) insider trading

Commercio interno	Relazione	Data	Transazione	Costo	#Azioni	Valore ($)	#Azioni Totale
Pande Vijay Satyanand	Director	Oct 01 '24	Buy	19.73	126,793	2,501,626	1,026,793
Pande Vijay Satyanand	Director	Oct 02 '24	Buy	19.73	67,096	1,323,804	1,093,889
Pande Vijay Satyanand	Director	Oct 03 '24	Buy	19.90	25,306	503,589	1,119,195
Cormorant Asset Management, LP	Former 10% Owner	Sep 27 '24	Buy	18.00	450,000	8,100,000	1,629,529
Pande Vijay Satyanand	Director	Sep 27 '24	Buy	18.00	900,000	16,200,000	900,000
ENRIGHT PATRICK G	Director	Sep 27 '24	Buy	18.00	400,000	7,200,000	1,710,589
HEALY JAMES	Director	Sep 27 '24	Buy	18.00	666,665	11,999,970	2,227,124

Bioage Labs Inc (BIOA)

Bioage Labs Inc Stock (BIOA) Company Profile

Confronta BIOA con altri titoli

Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades

Bioage Labs Inc Borsa (BIOA) Ultime notizie

BioAge to analyze 17,000 HUNT Biobank samples for aging research By Investing.com - Investing.com Nigeria

BioAge Labs to Profile Norwegian Biobank for Aging Drug Discovery - MarketScreener

BioAge Labs expands drug discovery platform with data from HUNT Biobank - TipRanks

BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank - Yahoo Finance

BioArctic to initiate next cohorts in exidavnemab Phase 2a study after positive safety review - marketscreener.com

Healthcare companies chase cures and capital in South Florida - Sun Sentinel

An Investigation Has Commenced on Behalf of BioAge Labs, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your BIOA Losses. - ACCESS Newswire

BioAge Labs Elects Directors at Annual Meeting - TipRanks

BIOA CLASS ACTION ALERT: BioAge Labs's 76% Stock Drop Triggers Securities Fraud Class Action; Contact BFA Law before March 10 Deadline - ACCESS Newswire

Lead Plaintiff Appointed in BioAge Labs Class Action — Here’s How You Can Recover Your Losses - TradingView

BioAge Labs, Inc. Announces Updates on APJ Agonist Program Updates - marketscreener.com

BioAge Labs Updates Milestones for NLRP3 Program - TipRanks

Bioage advances apelin receptor agonist program with option to Jikang’s nanobody - BioWorld MedTech

BioAge deepens weight loss R&D with fresh apelin receptor push - The Pharma Letter

BioAge Labs expands APJ agonist pipeline with biologic candidates - TipRanks

BioAge Labs Enters Option Agreement with JiKang Therapeutics to In-License Novel APJ Agonist Antibody and Expands Intellectual Property for Small Molecule APJ Agonists - Nasdaq

BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates - The Manila Times

Breakthrough Obesity Drug Pipeline: BioAge's New Treatment Doubles GLP-1 Weight Loss Effect - Stock Titan

Analysts Offer Insights on Healthcare Companies: Talkspace (TALK) and BioAge Labs, Inc. (BIOA) - The Globe and Mail

Bioage plans mid-year IND submission for BGE-102 for obesity - BioWorld MedTech

BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic - Pipelinereview

BioAge advances obesity drug into clinical trials By Investing.com - Investing.com South Africa

BioAge Labs, Inc. (BIOA)’s BGE-102 Shows Potent Weight Loss, Plans IND Submission Mid-2025 - Insider Monkey

Jefferies maintains hold on BioAge Labs with $4 target By Investing.com - Investing.com India

Jefferies maintains hold on BioAge Labs with $4 target - Investing.com

BioAge Labs, Inc. Completes IND-enabling Studies for BGE-102 - marketscreener.com

BioAge advances obesity drug into clinical trials - Investing.com Australia

BioAge Labs completes IND-enabling studies for BGE-102, a - GlobeNewswire

BioAge Labs to Present at Upcoming Investor Conferences - The Manila Times

BioAge Labs Announces Major Investor Presentations: Key Updates Expected at Global Healthcare Conferences - Stock Titan

BIOAGE ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire

Class Action Filed Against BioAge Labs, Inc. (BIOA) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire

BioAge Leaders Touted Obesity Drug Before Safety Woes, Suit Says - Bloomberg Law News

Invitation to presentation of BioArctic's first quarter report for JanuaryMarch 2025 on May 21 at 9.30 a.m. CET - Stock Titan

Investors who Lost Money on BioAge Labs, Inc. (BIOA) Should Contact Levi & Korsinsky About Pending Class ActionBIOA - ACCESS Newswire

Cautious Outlook on BioAge Labs, Inc. Amid Program Setbacks and Financial Concerns - TipRanks

Lost Money on BioAge Labs, Inc. (BIOA)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire

Levi & Korsinsky Notifies Shareholders of BioAge Labs, Inc.(BIOA) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire

Levi & Korsinsky Notifies Shareholders of BioAge Labs, Inc. (BIOA) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire

Levi & Korsinsky Notifies BioAge Labs, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineBIOA - ACCESS Newswire

Investors in BioAge Labs, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights – BIOA - ACCESS Newswire

BioAge Labs, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud AllegationsBIOA - ACCESS Newswire

Levi & Korsinsky Reminds BioAge Labs, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities LawsBIOA - ACCESS Newswire

BioAge Labs Advances Pipeline with Strategic Collaborations - TipRanks

BioAge Labs, Inc Q1 Loss Narrows - Nasdaq

BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates - The Manila Times

With 44% stake, BioAge Labs, Inc. (NASDAQ:BIOA) seems to have captured institutional investors' interest - Yahoo Finance

Press Release Distribution & PR Platform - ACCESS Newswire

INVESTOR DEADLINE MONDAY: BioAge Labs, Inc. Investors with Subst - GuruFocus

Shareholder Rights Advocates at Levi & Korsinsky Investigate BioAge Labs, Inc. (BIOA) Regarding Possible Securities Fraud Violations - ACCESS Newswire

BioAge Labs, Inc. Investigated Regarding Potential Securities Law ViolationsContact Levi & Korsinsky for Details- BIOA - ACCESS Newswire

Bioage Labs Inc Azioni (BIOA) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Bioage Labs Inc Azioni (BIOA) insider trading

Simile a BIOA